Identification and treatment of cancer subsets
The present invention relates to methods of selectively treating a patient with skin squamous cell carcinoma are disclosed. Specifically, the methods comprise assessing whether or not the tumor will be responsive to IP6 treatment by using reduced INPP5A expression level as an indicator. The present invention further provides methods of assessing the progression of the disease, and kits that facilitate these methods as disclosed.
1. A method of treating a subject having skin squamous cell carcinoma, the method comprising the steps of:
testing the subject for tumor cells with reduced activity in the inositol polyphosphate5-phosphatase (INPP5A) pathway in comparison to a control in order to determine that the tumor cells are sensitive to a pharmaceutical composition comprising inositol hexaphosphate (IP6) and pharmaceutically acceptable salts thereof, wherein testing the subject for tumor cells with reduced activity in the INPP5A pathway consists of detecting the gene expression of INPP5A by hybridization with an oligonucleotide complementary to a portion of SEQ ID NO:1 or detecting the protein expression of INPP5A with an antibody that binds to a portion of SEQ ID NO:2; and
administering an effective amount of the pharmaceutical composition to the subject when the subject is determined to have tumor cells that are sensitive to the pharmaceutical composition.
2. The method of claim 1 , wherein testing the subject for tumor cells with reduced activity in the INPP5A pathway in order to determine that the tumor cells are sensitive to a pharmaceutical composition further comprises receiving a sample from the subject.
3. The method of claim 1 , wherein the control is selected from the group consisting of normal skin tissue, normal skin adjacent to the tumor of the same subject, skin tissue from a less progressed tumor including actinic keratosis and squamous cell carcinoma in situ of the same subject.
4. The method of claim 1 , wherein the administering an effective amount of the pharmaceutical composition to the subject is selected from the group consisting of oral administration, topical administration, and parenteral administration.
5. The method of claim 2 , wherein the sample comprises a skin sample.
6. The method of claim 2 , wherein the sample comprises a cell selected from the group consisting of an actinic keratosis cell, a squamous cell carcinoma in situ cell, a squamous cell carcinoma cell, and a metastatic squamous cell carcinoma cell.
7. The method of claim 1 , wherein reduced activity in the INPP5A pathway is determined to be caused by deletion of at least one copy of INPP5A at chromosome 10q26.3.